Quotient Wealth Partners LLC Sells 8,130 Shares of Johnson & Johnson (NYSE:JNJ)

Quotient Wealth Partners LLC decreased its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 38.1% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 13,222 shares of the company’s stock after selling 8,130 shares during the period. Quotient Wealth Partners LLC’s holdings in Johnson & Johnson were worth $1,933,000 at the end of the most recent reporting period.

Other hedge funds have also added to or reduced their stakes in the company. Christopher J. Hasenberg Inc bought a new position in shares of Johnson & Johnson during the 1st quarter worth about $31,000. WFA Asset Management Corp boosted its position in shares of Johnson & Johnson by 61.4% during the 4th quarter. WFA Asset Management Corp now owns 255 shares of the company’s stock worth $40,000 after purchasing an additional 97 shares in the last quarter. MFA Wealth Advisors LLC bought a new position in shares of Johnson & Johnson during the 2nd quarter worth about $43,000. Vermillion & White Wealth Management Group LLC bought a new position in shares of Johnson & Johnson during the 4th quarter worth about $44,000. Finally, Disciplined Equity Management Inc. bought a new position in shares of Johnson & Johnson during the 4th quarter worth about $45,000. 69.55% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

JNJ has been the topic of a number of research analyst reports. Cantor Fitzgerald reissued an “overweight” rating and set a $215.00 price objective on shares of Johnson & Johnson in a research report on Monday, August 5th. Morgan Stanley increased their price objective on shares of Johnson & Johnson from $167.00 to $169.00 and gave the stock an “equal weight” rating in a research report on Thursday, July 18th. TD Securities dropped their price target on shares of Johnson & Johnson from $195.00 to $185.00 in a research report on Thursday, July 18th. TD Cowen dropped their price target on shares of Johnson & Johnson from $195.00 to $185.00 and set a “buy” rating on the stock in a research report on Thursday, July 18th. Finally, Daiwa America cut shares of Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 23rd. Seven investment analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $173.21.

Johnson & Johnson Trading Up 1.1 %

Shares of JNJ stock opened at $164.13 on Friday. The company has a 50 day moving average of $153.92 and a 200-day moving average of $153.24. The company has a quick ratio of 0.85, a current ratio of 1.07 and a debt-to-equity ratio of 0.44. Johnson & Johnson has a 12-month low of $143.13 and a 12-month high of $167.78. The firm has a market cap of $395.01 billion, a P/E ratio of 10.23, a PEG ratio of 2.63 and a beta of 0.52.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Wednesday, July 17th. The company reported $2.82 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.71 by $0.11. Johnson & Johnson had a net margin of 46.34% and a return on equity of 36.60%. The company had revenue of $22.45 billion during the quarter, compared to analyst estimates of $22.33 billion. During the same quarter last year, the business posted $2.80 EPS. Johnson & Johnson’s quarterly revenue was up 4.3% compared to the same quarter last year. Sell-side analysts anticipate that Johnson & Johnson will post 10.07 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 10th. Investors of record on Tuesday, August 27th will be issued a $1.24 dividend. This represents a $4.96 annualized dividend and a yield of 3.02%. The ex-dividend date is Tuesday, August 27th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 30.92%.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.